

P29491.P05


FORM PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
P29491Application No.
10/517,324

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary) NOV 27 2006

Applicant
Susumu MUTO et al.Filing Date
I.A. Filed September 3, 2004Group
Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	8	- 0 9 5 2 0 8	04/12/96	JAPAN			
	60	- 1 5 6 3 8 7	08/16/85	JAPAN			
	0	0 / 3 2 5 9 8	06/08/06	W.I.P.O.			
	0	1 / 5 7 0 0 6	08/09/01	W.I.P.O.			
		1 1 1 9 4 3 6	12/14/61	GERMANY			
	2004	/ 0 2 4 0 6 1	03/25/04	W.I.P.O.			
	9	5 / 3 2 1 9 0	11/30/95	W.I.P.O.			
	9	5 / 2 1 8 3 2	08/17/95	W.I.P.O.			
		2 3 7 2 7 4 0	09/04/02	UNITED KINGDOM			
	03	/ 0 0 0 2 5 3	01/03/03	W.I.P.O.			
	03	/ 0 0 0 2 5 8	01/03/03	W.I.P.O.			
	03	/ 0 0 0 6 4 9	01/03/03	W.I.P.O.			
	03	/ 0 0 0 6 7 1	01/03/03	W.I.P.O.			
	03	/ 0 0 0 6 8 4	01/03/03	W.I.P.O.			
	02	/ 0 6 4 0 6 8	08/22/02	W.I.P.O.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	English Language Abstract of JP 8-095208.
2	English Language Abstract of JP 60-156387.
3	English Language Chemical Abstract of DE 11 19 436.
4	SCHNEIDERMAN et al. "Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries", Proceedings in the National Academy of Science U.S.A., vol. 89 (1992), pp. 6998-7002.
5	ERICKSON et al. "Development of Venous Occlusions in Mmice Transgenic for the Plasminogen Activator Inhibitor-1 gene", Nature, vol. 346 (1990), pp. 74-76.
6	SAMAD et al. "Tissue Distribution and Regulation of the Plasminogen Activator Inhibitor-1 in Obese Mice", Molecular Medicine, vol. 2, No. 5 (1996), pp. 568-582.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449			U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P29491	Application No. 10/517,324
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			NOV 27 2006 RECEIVED U.S. PATENT AND TRADEMARK OFFICE		
			Applicant Susumu MUTO et al.		
			Filing Date I.A. Filed September 3, 2004	Group Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	7	SCHÄFER et al. "Disruption of the Plasminogen Activator Inhibitor 1 Gene reduces the Adiposity and improves the Metabolic Profile of Genetically Obese and Diabetic ob/ob Mice", FASEB Journal, vol. 15, No. 10 (2001), pp. 1840-1842.			
	8	TSUCHIYA et al. "The Antibody to Plasminogen Activator Inhibitor-1 suppresses Pulmonary Metastases of Human Fibrosarcoma in Athymic Mice", General and Diagnostic Pathology, vol. 141 (1995), pp. 41-48.			
	9	BAJOU et al. "Absence of Host Plasminogen and Activator Inhibitor-1 prevents Cancer Invasion and Vascularization", Nature Medicine, vol. 4, no. 6 (1998), pp. 923-928.			
	10	CHO et al. "Production of Plasminogen Activator Inhibitor-1 by Human Mast Cells and Its Possible Role in Asthma", The Journal of Immunology, vol. 165, no. 6 (2000), pp. 3154-3161.			
	11	OH et al. "PAI-1 promotes Extracellular Matrix Deposition in the Airways of a Murine Asthma Model", Biochemical and Biophysical Research Communications, vol. 294 (2002), pp. 1155-1160.			
	12	BJÖRQUIST et al. "Identification of the Binding Site for a Low-Molecular-Weight Inhibitor of Plasminogen Activator Inhibitor Type 1 by Site-Directed Mutagenesis", Biochemistry, vol. 37 (1998), 1227-1234.			
	13	MITSUNOBU "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products", Synthesis (1981), pp. 1-28.			
	14	DÜRÜST "A New and Convenient Synthesis of some Substituted Thiohydantoins", Synthetic Communications, vol. 29, no. 11 (1999), pp. 1997-2005.			
	15	KOZUMA "Drug Eluting Stent", Coronary Intervention, vol. 1, no. 1 (2002), pp. 58-62, accompanied by an English language translation thereto.			
	16	HIATT et al. "Drug-Eluting Stents for the Prevention of Restenosis: In Quest for the Holy Grail", Catheterization and Cardiovascular Interventions, vol. 55 (2002), pp. 409-417.			
	17	CURFMAN "Sirolimus-Eluting Coronary Stents," New England Journal of Medicine, vol. 346, no. 23 (2002), pp. 1770-1771.			
	18	MORICE et al. "A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization," New England Journal of Medicine, vol. 346, no. 23 (2002), pp. 1773-1780.			
EXAMINER /Dana Shin/			DATE CONSIDERED 07/20/2010		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					